id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-0263-0008,FDA,FDA-2013-E-0263,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-03-21T04:00:00Z,2018,3,2018-03-21T04:00:00Z,,2018-03-21T12:40:35Z,,0,0,09000064830359d5
FDA-2013-E-0263-0007,FDA,FDA-2013-E-0263,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RECUVYRA; Affirmation",Notice,Determinations,2017-08-23T04:00:00Z,2017,8,2017-08-23T04:00:00Z,,2017-08-23T14:14:05Z,2017-17961,0,0,0900006482a9fe28
FDA-2013-E-0263-0006,FDA,FDA-2013-E-0263,Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA,Notice,Determinations,2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,2018-02-21T04:59:59Z,2017-08-21T15:53:20Z,2017-17566,0,0,0900006482a8d15e
FDA-2013-E-0263-0005,FDA,FDA-2013-E-0263,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-06T04:00:00Z,2017,6,2017-06-06T04:00:00Z,,2017-06-06T14:13:14Z,,0,0,090000648269719e
FDA-2013-E-0263-0004,FDA,FDA-2013-E-0263,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T19:15:08Z,,0,0,090000648243b983
FDA-2013-E-0263-0003,FDA,FDA-2013-E-0263,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-02T04:00:00Z,2016,5,2016-05-02T04:00:00Z,,2016-05-02T23:12:42Z,,0,0,0900006481fa1c70
FDA-2013-E-0263-0001,FDA,FDA-2013-E-0263,Acrux DDS Pty Ltd - Patent Extension Application,Other,Application,2013-03-08T05:00:00Z,2013,3,2013-03-08T05:00:00Z,,2013-03-08T15:06:03Z,,0,0,09000064812209e9
FDA-2013-E-0263-0002,FDA,FDA-2013-E-0263,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-03-08T05:00:00Z,2013,3,2013-03-08T05:00:00Z,,2013-03-08T15:09:12Z,,0,0,09000064812209ed